Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Quantum Biopharma ( (TSE:QNTM) ) has shared an update.
Quantum BioPharma Ltd. announced on May 30, 2025, that it has reached a global settlement agreement with its former CEO, Dr. Raza Bokhari, resulting in a $2.35 million USD non-dilutive cash payment to the company. This settlement resolves all disputes originating from a proxy contest that began in January 2021, bringing closure to various legal issues and preventing future litigation in Canada and the U.S. The settlement is expected to positively impact Quantum BioPharma’s financial position and operational focus.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for treating neurodegenerative, metabolic disorders, and alcohol misuse disorders. The company is advancing its lead compound, Lucid-MS, which targets multiple sclerosis, and maintains strategic investments through its subsidiary, FSD Strategic Investments Inc.
Average Trading Volume: 8,050
Technical Sentiment Signal: Hold
Current Market Cap: C$46.67M
Learn more about QNTM stock on TipRanks’ Stock Analysis page.